Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKR 202 in osteoarthritis knee pain
2013-001701-85Phase 2Completed
- Sponsor
- Akron Molecules AG
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) and osteoarthritis (OA) comparing AKR 202 with Placebo (2 arms). Primary endpoint: Change from baseline in WOMAC pain subscale at Week 8 or final visit. Started Jul 2013; status: completed.
02
Drugs
adefovir dipivoxil
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on 2013-001701-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001701-85.